Unified applications for clinical, regulatory, and quality help fast-growing start-up drive greater efficiency and compliance throughout development<\/em><\/p>\n BARCELONA, Spain \u2014 10 July 2018 \u2014 <\/strong> ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE:VEEV) today announced that Idorsia Pharmaceuticals Ltd established an integrated development landscape with ³Ô¹Ï±¬ÁÏ Development Cloud<\/a>. With unified applications for clinical, regulatory, and quality on a single cloud platform, Idorsia now has the technology foundation to accelerate product innovation and support its global growth plans.<\/p>\n \u201cWith a strong pipeline of innovative new therapies, we needed cutting-edge cloud technology that could scale as we grow,\u201d said Joseph Bejjani, CIO at Idorsia. \u201cOur IT strategy had three guiding principles when it came to product selection \u2013 cloud-first, easy-to-use functionality, and integrated, platform-based solutions. ³Ô¹Ï±¬ÁÏ met all three objectives within a very tight timeline.\u201d<\/p>\n Idorsia is a fast-growing biopharmaceutical start-up focused on research and early-stage clinical development. Immediately after its founding, Idorsia set an aggressive timeline to transition to new clinical development systems within 12 months.<\/p>\n With ³Ô¹Ï±¬ÁÏ Development Cloud, Idorsia has unified applications to streamline documents and workflows so teams have a single source of truth across clinical, regulatory, and quality. This eliminates manual, duplicative efforts and gives teams consistent information throughout clinical development. Because ³Ô¹Ï±¬ÁÏ Vault applications have the same modern and intuitive interface, teams work with greater speed and spend less time on training.<\/p>\n \u201c³Ô¹Ï±¬ÁÏ gives us the right technology foundation to manage business processes, content, and data across the organization,\u201d said Simone Mechler, associate director clinical & quality systems. \u201cWe exceeded our goal and went live within seven months. All regions and departments now have a consistent view of the products in development to drive greater operational efficiency and maintain compliance.\u201d<\/p>\n Idorsia is using or plans to use multiple applications across ³Ô¹Ï±¬ÁÏ Development Cloud suites, including Vault eTMF<\/a> and Vault CTMS<\/a> from Vault Clinical Suite<\/a>; Vault Registrations<\/a>, Vault Submissions<\/a>, and Vault Submissions Publishing<\/a> from Vault RIM Suite<\/a>; and Vault QMS<\/a> and Vault QualityDocs<\/a> from Vault Quality Suite<\/a>.<\/p>\n \u201cIdorsia needed to bring together their applications for clinical, quality, and regulatory to streamline drug development,\u201d said Rik Van Mol, vice president, R&D strategy, Europe at ³Ô¹Ï±¬ÁÏ. \u201c³Ô¹Ï±¬ÁÏ Development Cloud helps life sciences companies like Idorsia achieve alignment across headquarters, sites, and countries and increases communication, collaboration, and compliance across the functions.\u201d<\/p>\n Additional Information<\/strong> About ³Ô¹Ï±¬ÁÏ Systems<\/strong> Forward-looking Statements<\/strong> ###<\/p>\n Contact:<\/strong> Idorsia drives efficient, compliant development with unified clinical, regulatory, and quality applications.<\/p>\n","protected":false},"featured_media":20377,"parent":0,"template":"","class_list":["post-20371","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-data-management","resource-area-20-clinical-operations","resource-area-20-development-cloud-a","resource-area-20-quality","resource-area-20-regulatory","resource-area-20-research-sites","resource-area-20-safety","resource-product-20-batch-release","resource-product-20-ctms","resource-product-20-development-cloud","resource-product-20-disclosures","resource-product-20-dqs","resource-product-20-epro","resource-product-20-edc","resource-product-20-eisf","resource-product-20-esource","resource-product-20-etmf","resource-product-20-vault-lims","resource-product-20-vault-medcomms","resource-product-20-medical-insights","resource-product-20-vault-medinquiry","resource-product-20-payments","resource-product-20-postmarket-surveillance","resource-product-20-publications","resource-product-20-qms","resource-product-20-qualitydocs","resource-product-20-reference-data-opendata-clinical","resource-product-20-registrations","resource-product-20-rtsm","resource-product-20-safety2","resource-product-20-safety-content","resource-product-20-safety-signal","resource-product-20-safety-workbench","resource-product-20-site-connect","resource-product-20-sponsor-site-collaboration","resource-product-20-station-manager","resource-product-20-study-startup","resource-product-20-study-training","resource-product-20-submissions","resource-product-20-submissions-archive","resource-product-20-submissions-publishing","resource-product-20-training","resource-product-20-vault-validation-management","resource-type-news-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/20371"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":2,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/20371\/revisions"}],"predecessor-version":[{"id":86593,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/20371\/revisions\/86593"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/20377"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=20371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nFor more on ³Ô¹Ï±¬ÁÏ Development Cloud, visit: veeva.com\/³Ô¹Ï±¬ÁÏDevelopmentCloud<\/a>
\nConnect with ³Ô¹Ï±¬ÁÏ on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @³Ô¹Ï±¬ÁÏ_EU on Twitter: twitter.com\/veeva_eu <\/a>
\nLike ³Ô¹Ï±¬ÁÏ on Facebook: facebook.com\/veevasystems<\/a><\/p>\n
\n³Ô¹Ï±¬ÁÏ Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ has more than 625 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.<\/p>\n
\nSue Glanville \/ Cate Bonthuys
\n³Ô¹Ï±¬ÁÏ Systems Inc.
\nsue@catalystcomms.co.uk<\/a> \/ cate@catalystcomms.co.uk<\/a>
\n+44 (0) 7715 817589 \/ +44 (0) 7746 546773<\/p>\n","protected":false},"excerpt":{"rendered":"